Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, May 20, 11:38 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Thursday, May 17


News

Global Infertility Treatment Market 2018-2022: Key Players are AbbVie, Cook Group, Ferring, Merck, The Cooper Companies & Vitrolife - ResearchAndMarkets.com

MRK ABBV

Global Infertility Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. According to the fertility market overview, the rising incidences of lifestyle diseases will be one of the key factors impelling a positive impact on the infertility treatment market in the forthcoming years. With the growing popularity of technologies and digital innovations, vendors in the infertility treatment market are focusing improving the access to these services by offering personalized medicine via various ART procedures.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, May 16


News

Top Analyst Reports for Home Depot, Merck & Raytheon

MRK HD +1 more MRK HD RTN

Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Merck (MRK) and Raytheon (RTN). The Zacks analyst thinks that this performance is attributable to its five-year long trend of beating earnings estimates, which continued in first-quarter fiscal 2018. The Zacks analyst thinks that new products like Keytruda, Lynparza, and Bridion should continue to contribute meaningfully to the top line in 2018. Raytheon’s shares have risen around +14.5% over the last six months, outperforming the Zacks Defense Equipment industry, which has increased +10.7% over the same period. However, Raytheon kick started 2018 on a solid note.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, May 15


News

Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

MRK

Net sales in the reported quarter came in at €3.7 billion ($4.5 billion), down 4.4%, including unfavorable foreign exchange which hurt sales by 7.9%. However, organic sales growth of 3.5% was driven by the Healthcare and Life Science segment. The company declined 7.1% while the industry increased 0.8% in the same period. Newly launched Bavencio and Mavenclad registered sales of €12 million and €13 million, respectively. In March, the company received €50 million in milestone payment from BioMarin, Inc. BMRN as the latter announced the acceptance of a marketing authorization application for Peg-Pal for the treatment of phenylketonuria by the EMA.

Read Full Details

Topics:
  • Business
  • Financial
News
News

Merck KGaA sales hurt by currency China headwinds

MRK

Merck KGaA (MRK.XE) shares fell by as much as 4.8% in early trade Tuesday after the company said that, despite organic growth, its first-quarter sales declined, dragged by currency headwinds and continuing market-share decline in performance materials in China. The company reported a 4.4% group sales decline to 3.69 billion euros ($4.41 billion), affected by negative exchange rates. Sales in its performance-materials division decreased 12% to EUR564 million, with Chinese competition in liquid crystals amplifying the decline, the company said. The planned sale of its consumer-health business to Procter & Gamble Co. PG-0.67% is likely to reduce group sales by between EUR900 million and EUR1 billion, lowering sales estimates to between EUR14 billion and EUR14.5 billion, it said.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

Merck KGaA Q1 earnings down on liquid crystals, currencies

MRK

* Q1 adj EBITDA down 18 pct, in line with view. FRANKFURT, May 15 (Reuters) - Germany's Merck KGaA saw earnings decline in the first quarter and predicted a drop for the full year, hurt by Chinese competition in liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales. Merck on Tuesday reported 1.02 billion euros ($1.22 billion) in first quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA), down 18 percent and in line with market expectations. The chemicals and drugs maker said it expected adjusted EBITDA from continuing operations to decline to 3.75 to 4.0 billion euros in 2018, stripping out 170 to 200 million euros from the consumer healthcare unit it has agreed to sell to Procter & Gamble for 3.4 billion euros.

Read Full Details

Topics:
  • Business
  • Financial

Monday, May 14


News

What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

MRK

Merck KGaA MKGAF is scheduled to report first-quarter 2018 results on May 15. The company reports results under three business sectors — Healthcare, Life Science and Performance Materials. In December 2017, Merck’s multiple sclerosis drug, Mavenclad was approved in Australia and Canada, following its approval in Europe in the third quarter of 2017. Expenses are estimated to increase in the first quarter as the company focuses on the development of an innovative pipeline, launch of Bavencio in new geographies as well as Mavenclad.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, May 13


News

Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)

MRK PFE

Both pharmaceutical companies have successful products with sizzling sales, but both have experienced headwinds that have weighed on their overall revenue and earnings growth. Growth. Although quarterly results present only a snapshot of a company's performance, it's still helpful to see how Pfizer and Merck performed in the last quarter. Wall Street analysts project that Pfizer will be able to generate average annual earnings growth of 7% over the next five years, while they expect Merck's average annual earnings growth to be a little over 6% during the same period. Merck also continues to see strong sales growth for its HPV vaccine Gardasil and should benefit from the launch of diabetes drug Steglatro, which it co-markets with Pfizer. What about Merck's pipeline?

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, May 11


News

Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings? - May 11, 2018

MRK PFE

Both Merck & Co., Inc. MRK and Pfizer, Inc. PFE reported upbeat first-quarter results on May 1. In fact, both pharma giants managed to outpace their earnings estimate but missed on the revenue front. However, the companies’ top and bottom lines rose year over year. In the first quarter, Merck reported adjusted earnings per share of $1.05, surpassing the Zacks Consensus Estimate by six cents. Merck has witnessed a rise of 5.8% in the past three months, while Pfizer has advanced only 2.6%. So Merck is a clear winner in this respect with better returns than both rival Merck and the broader industry, which declined 2% during the same period.

Read Full Details

Topics:
  • Business
  • Financial
News

Keytruda Continues to Be Major Growth Driver for Merck in 2018

MRK

In 1Q18, Merck’s (MRK) Keytruda reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of around 151%. The rise was attributable to the highest number of new patient starts for Keytruda in the US as compared to other immunotherapy drugs such as Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tecentriq. The drug has established itself as a leading therapy for metastatic lung cancer in the US.

Read Full Details

Topics:
  • Business
  • Health